AsclepiX Therapeutics

Share on: 
Business Area(s): 

AsclepiX Therapeutics is revolutionizing the treatment of retinal diseases and cancer with a singular focus on the design, development, and delivery of novel peptides with the power to inhibit proven key disease pathways.

Our lead candidate, AXT107 inhibits VEGF and activates Tie 2, the only two clinically validated pathways for the treatment of serious diseases of the retina.

Baltimore MD
United States
Jersey City NJ
United States